Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PKA/PKC Kinase Assay from Article 10.1016/j.bmcl.2006.03.041: "Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity."
Assay data:4 Active, 1 Activity ≤ 1 nM, 4 Activity ≤ 1 µM, 4 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Target
Akt Kinase Assay from Article 10.1016/j.bmc.2007.01.010: "Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt."
Assay data:16 Active, 3 Activity ≤ 1 nM, 16 Activity ≤ 1 µM, 16 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
PKA/PKC Kinase Assay from Article 10.1021/jm0701019: "Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase b/akt inhibitors with reduced hypotension."
Assay data:9 Active, 9 Activity ≤ 1 µM, 10 Tested
PKA In Vitro Enzyme Assay from Article 10.1021/jm0700924: "Rapid Evolution of 6-Phenylpurine Inhibitors of Protein Kinase B through Structure-Based Design."
Assay data:7 Active, 5 Activity ≤ 1 µM, 7 Tested
PKA In Vitro Enzyme Assay from Article 10.1016/j.jmb.2007.01.004: "A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera."
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
PKA In Vitro Enzyme Assay from Article 10.1016/j.bmc.2005.09.055: "Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B."
Assay data:12 Active, 8 Activity ≤ 1 µM, 12 Tested
PKA/PKC Kinase Assay from Article 10.1016/j.bmcl.2006.04.046: "Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase."
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
PKA/PKC Kinase Assay from Article 10.1016/j.bmcl.2005.12.017: "Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation."
PKA/PKC Kinase Assay from Article 10.1016/j.bmcl.2005.12.065: "Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer."
Assay data:3 Active, 3 Activity ≤ 1 µM, 3 Tested
Kinase Activity Assay from Article 10.1074/jbc.M512374200: "Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity."
Assay data:5 Active, 5 Activity ≤ 1 µM, 5 Tested
Fluorescence Polarization-based Assay from Article 10.1021/jm0310479: "Structure-based optimization of novel azepane derivatives as PKB inhibitors."
Assay data:5 Active, 5 Activity ≤ 1 µM, 6 Tested
Fluorescence Polarization-based Assay from Article 10.1021/jm049701n: "Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants."
Assay data:5 Active, 2 Activity ≤ 1 µM, 5 Tested
Kinase Inhibition Assay from Article 10.1016/j.bmcl.2004.01.050: "Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum."
Assay data:7 Active, 6 Activity ≤ 1 µM, 10 Tested
Kinase Inhibition Assay from Article 10.1021/jm011020u: "First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease."
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Target
Kinase Inhibition Assay from Article 10.1021/jm050267e: "1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities."
Assay data:15 Active, 3 Activity ≤ 1 nM, 14 Activity ≤ 1 µM, 16 Tested
Kinase Inhibition Assay from Article 10.1021/jm0256169: "Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors."
Assay data:12 Active, 10 Activity ≤ 1 µM, 13 Tested
CDK Kinase Inhibition Assay from Article 10.1016/s0960-894x(03)00461-x: "Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles."
Assay data:68 Active, 68 Activity ≤ 1 µM, 72 Tested
CDK Kinase Inhibition Assay from Article 10.1016/S0960-894X(03)00792-3: "Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides."
Assay data:22 Active, 17 Activity ≤ 1 µM, 22 Tested
CDK Kinase Inhibition Assay from Article 10.1016/j.bmcl.2004.04.033: "Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors."
Assay data:17 Active, 17 Activity ≤ 1 µM, 18 Tested
CDK Kinase Inhibition Assay from Article 10.1016/j.bmcl.2004.05.088: "Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors."
Assay data:12 Active, 12 Activity ≤ 1 µM, 12 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on